Tick-borne Encephalitis (TBE)
Vaccines Forecast
Tick-borne encephalitis virus is a flavivirus transmitted by infected Ixodes ticks across a vast endemic belt running from central and eastern Europe, through Russia, to the islands of northern Japan. Reported TBE incidence has been rising, and the endemic footprint expanding, across Europe since 2017, driven in part by climate-linked changes in tick habitat and activity, yet Encepur (Bavarian Nordic) and FSME-IMMUN, marketed in the US as TicoVac (Pfizer), remain the only licensed vaccines worldwide. This is a comprehensive, endemic-market commercial assessment of the TBE vaccine opportunity to 2035, drawing on VacZine Analytics' long standing, independent authority in travel disease vaccine markets.
- Format
- Executive presentation + Excel model
- Coverage
- Endemic European/Eurasian markets
- Indications
- TBE prevention, endemic & traveler
- Forecast horizon
- To 2035
- Approach
- Value ($m)/volume (mio doses) model
- Base edition
- For order only
- Availability
- Syndicated / bespoke
EU/EEA countries in 2022, up 14%
its still-continuing rise in Europe
predominant European TBEV subtype
Encepur & FSME-IMMUN/TicoVac
A rising, spreading flavivirus with only decades-old vaccines to meet it
This review sets out TBE virology and transmission, its clinical spectrum, and the latest epidemiological evidence for a disease whose incidence and geographic footprint are both moving in the wrong direction.
Pathogen overview - Tick-borne encephalitis virus (TBEV)
Tick-borne encephalitis virus (TBEV) is a flavivirus in the same family as yellow fever, Japanese encephalitis and dengue viruses. It is transmitted to humans principally through the bite of infected Ixodes ticks, Ixodes ricinus across central and western Europe and Ixodes persulcatus further east, which acquire and maintain the virus in a natural cycle involving small rodents and other wild mammals. Three main TBEV subtypes are recognised, European, Siberian and Far Eastern, and they differ meaningfully in severity: the European subtype carries a case-fatality rate of under 2%, the Siberian subtype around 6-8% with a recognised risk of chronic, slowly progressive encephalitis in children, and the Far Eastern subtype 20-40% among those with neurological disease.
Most TBEV infections are mild or asymptomatic, but a substantial minority progress to neuroinvasive disease, meningitis, meningoencephalitis, encephalomyelitis and paralytic forms resembling poliomyelitis. Among patients with European-subtype neuroinvasive disease, an estimated 20-40% (with some series reporting up to 40-50%) go on to experience long-term or permanent sequelae, including limb paresis or paralysis in up to around 10% of cases and neuropsychiatric after-effects, persistent cognitive, mood or sleep-wake disturbance, in a further 10-20%. There is no specific antiviral treatment; management is supportive, which is precisely why vaccination, rather than post-exposure treatment, sits at the centre of TBE control policy in endemic countries.
ECDC surveillance confirms that after a broadly stable long-term trend, reported TBE incidence across the EU/EEA has been on a gradual, sustained rise since 2017. In 2022, the most recent full annual total available, 20 EU/EEA countries reported 3,650 TBE cases (96.3% laboratory-confirmed), an EU/EEA notification rate of 0.81 per 100,000, up 14% on 2021's rate of 0.71 per 100,000 across 25 reporting countries. ECDC's most recent country-level notification-rate release, covering 2019 to 2023, was published in March 2025, and preliminary assessments of the 2024 season across multiple endemic countries point to a continued high disease burden, with several countries at risk of new peaks once late notifications are finalised. The prevailing scientific view links this rise substantially to climate-driven changes in tick habitat and activity: milder winters, longer tick-activity seasons and the documented northward and altitudinal expansion of Ixodes persulcatus and I. ricinus habitat are extending TBE risk into previously non-endemic or marginal areas of central, northern and eastern Europe.
TBEV's endemic range spans a broad Eurasian forest belt running from eastern France, Germany, Austria, Switzerland and the Baltic states, across central and Eastern Europe, Russia and Kazakhstan, to China, the Russian Far East and the northern Japanese island of Hokkaido. Highest-incidence countries have traditionally included the Baltic states, the Czech Republic, Slovenia and parts of Austria, Germany and Scandinavia, but ECDC and academic surveillance both describe a widening, rather than a static, endemic footprint, an important structural consideration for any vaccine demand model built for this market.
Two long-standing vaccines, a widening market, and early-stage research beyond them
The TBE vaccine market has been a stable, two-player field for decades. That stability now sits against a backdrop of rising, geographically expanding demand, and the first early academic moves toward a broader-coverage, next-generation alternative.
-
Bavarian NordicLicensed, endemic EuropeEncepur Inactivated whole-virus vaccine
Bavarian Nordic has marketed Encepur across endemic European markets since acquiring it from GSK (previously Novartis/Chiron) in October 2019. A revised Encepur SmPC took effect in Germany in May 2025, extending the approved booster interval and refining the vaccine's rapid "Express" three-dose priming schedule, in which all three primary doses are given within 21 days. -
PfizerLicensed, Europe & USFSME-IMMUN / TicoVac Inactivated whole-virus vaccine
Pfizer (previously Baxter) markets FSME-IMMUN across endemic European markets and, under the brand TicoVac, in the United States, where the FDA approved it in August 2021 for use from age 1 upward, the only FDA-approved TBE vaccine and the sole option specifically labelled for US travelers to, and residents of, endemic areas. -
Russian & CIS manufacturersLicensed, Russia/CISDomestic Russian TBE vaccines
Local Russian manufacturers continue to produce inactivated TBE vaccines for the Russian and wider CIS market, reflecting the country's own substantial TBE burden across its Siberian and Far Eastern endemic regions. -
Academic & biotech research groupsPreclinical, mRNA-basedNext-generation mRNA-LNP candidates
Multiple academic groups have begun evaluating mRNA-LNP TBE vaccine candidates in animal models, aiming to overcome first-generation inactivated vaccines' comparatively limited cross-protection against heterologous TBEV strains. As of early 2026 these programmes remain at the preclinical stage, with no candidate yet in clinical development. -
ECDC & national surveillance bodiesActive surveillanceSeasonal TBE notification & range monitoring
ECDC and national public health institutes across endemic countries continue to track TBE notification rates and geographic spread season by season, the primary real-world signal of the disease's continuing, climate-linked expansion.
Two inactivated whole-virus vaccines, essentially unchanged in mechanism for decades, remain the entirety of the licensed TBE vaccine market, even as reported incidence keeps climbing and the endemic footprint keeps widening. Early-stage mRNA-based research offers a longer-term route to broader cross-strain protection, but no next-generation candidate has yet reached clinical testing. That combination, a stable competitive landscape set against steadily rising, geographically expanding demand, materially shapes the near-term commercial forecast this report is built to quantify.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide endemic-market focus, spanning disease burden, the vaccine competitive landscape, target product profile design and scenario-based demand forecasting to 2035.
Value ($m) and volume (mio doses) demand modelling to 2035 across endemic European and Eurasian markets, by country.
Full review of Encepur, FSME-IMMUN/TicoVac, Russian-manufactured vaccines and early-stage next-generation mRNA research.
Ideal target product profile assessment for both existing inactivated vaccines and any future broader-coverage candidate.
Volume and value forecasts to 2035, reflecting alternative disease-incidence and market-upside scenarios.
Full epidemiological review, incidence rising since 2017 and the climate-driven expansion of the endemic footprint.
Designed as an ideal tool to aid decision making in TBE vaccine market entry, access strategy and investment planning.
A glimpse of the commercial model
The table below shows a partial view of the indication and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Indication / segment | Geography | Target group | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| TBE prevention - general population | Baltic states & Central Europe | Occupational / rural at-risk adults | Licensed (Encepur / FSME-IMMUN) | Modelled |
| TBE prevention - travelers | Non-endemic source markets | International & domestic travelers | Licensed (FSME-IMMUN/TicoVac) | Modelled |
| TBE prevention - paediatric | Endemic Central/Eastern Europe | Children aged 1 and above | Licensed | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All endemic geographies | All groups | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the TBE vaccine opportunity across endemic European and Eurasian markets.
- Executive presentation (PDF) - disease background, epidemiology, vaccine landscape and full commercial assessment with supporting narrative and references
- MS-Excel value/volume forecast model - demand outputs to 2035 across all relevant country markets and target groups
- Endemic-market coverage - country-level modelling across the Eurasian endemic belt from Central Europe to the Russian Far East
- Competitor intelligence - Encepur (Bavarian Nordic), FSME-IMMUN/TicoVac (Pfizer), Russian-manufactured vaccines and next-generation mRNA research
- Updated epidemiology module - ECDC surveillance data through 2022/23 and the climate-driven, geographically expanding incidence trend
- Early decision-making support - target product profile and market entry strategy guidance for TBE vaccine planning
Built for organisations evaluating the TBE vaccine opportunity
Most valuable to teams assessing the tick-borne encephalitis vaccine market against their own pipeline, BD ambitions or investment thesis, drawing on VacZine Analytics' long standing expertise in travel diseases.
Vaccine developers
Positioning, target product profile and commercial feasibility assessment for existing and any future TBE candidates.
Corporate strategy & BD
Validate the size and trajectory of an endemic market where demand is rising even as the competitive field stays stable.
Investors & analysts
Independent assessment of market structure and commercial upside for due diligence on TBE and wider travel vaccine entrants.
Public health & immunisation programmes
Demand modelling to support at-risk population and traveler vaccination programme planning in endemic and near-endemic regions.
Researchers & academia
Comprehensive epidemiology and R&D landscape review to support grant, translational and next-generation vaccine planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public immunisation and private traveler-health channels.
VacZine Analytics has long standing expertise in travel diseases, positioning us to track the tick-borne encephalitis vaccine market's slower-moving supply side against its faster-moving epidemiological trend. This is a genuinely comprehensive analysis with a wide endemic-market focus, spanning the full Eurasian TBE belt from Central Europe to the Russian Far East, and it has been well received by clients in the field for the depth of its epidemiological review and its country-level demand modelling. Few groups have followed this market as closely for as long, and that recognised, independent expertise underpins everything in the analysis.
This report is currently available for order only; no syndicated edition has yet been published. A first syndicated MarketVIEW edition would incorporate the latest ECDC surveillance data, the continuing rise and geographic expansion of TBE incidence since 2017, and the current status of Encepur and FSME-IMMUN/TicoVac, the field's only two licensed vaccines. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc TBE vaccine analysis, a briefing call is included on request.